Merck's antiviral pill molnupiravir up for evaluation


An FDA advisory panel meeting has been scheduled for Nov. 30 to evaluate Merck's antiviral pill molnupiravir, developed in partnership with Ridgeback Biotherapeutics, to treat mild-to-moderate COVID-19. Should the panel back its approval, the oral pill would be used in recently diagnosed COVID-19 patients at high risk for developing severe illness, becoming hospitalized or dying from a coronavirus infection.

Full story:

AIChE SmartBrief

Chemical engineering news

Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly e-mail newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.